Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.

Predictably, patients who achieved a major pathological response had a strong trend toward an improved PFS compared to those who did not.

also in 5,725 other papers

We found a nonsignificant trend toward greater frequency of PD1 + T cells at 3 months post-resection in patients who did not have an MPR but remained disease-free at the conclusion of the trial (Supplementary Fig.

also in 5,406 other papers